Safety and Efficacy of Amlitelimab in Patients With Atopic Dermatitis
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The British Journal of Dermatology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Safety and efficacy of amlitelimab, a fully human, non-depleting, non-cytotoxic anti-OX40Ligand monoclonal antibody, in atopic dermatitis: results of a phase IIa randomised placebo-controlled trial
Br J Dermatol 2023 Jul 18;[EPub Ahead of Print], S Weidinger, T Bieber, MJ Cork, A Reich, R Wilson, S Quaratino, M Stebegg, N Brennan, S Gilbert, JT O'Malley, B Porter-BrownFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.